What did you hope to learn from your genetic test … if you have ever had one?

There’s a very nice article today on the MedPage Today web site about the medical value of “at-home genetic testing” (i.e., the sorts of tests available from companies like 23&Me and some others). … READ MORE …

Commercially available liquid biopsy data may be misleading

A newly published research letter in JAMA Oncology is entitled “Patient-paired sample congruence between 2 commercial liquid biopsy tests”. The two tests are both said — by the companies that market them — to have high clinical sensitivity and specificity in the identification of specific genetic markers associated with high-risk forms of prostate cancer. … READ MORE …

FDA approves key genetic/genomic test for cancer mutations

According to reports from the Associated Press and others, some time late last Thursday the  US Food & Drug Administration (FDA) appears to have approved the use of the FoundationOne CDx genetic/genomic test for patients with “advanced or widely spread cancers.” A media release from Foundation Medicine is also available on line. … READ MORE …

The role of the phi test prior to decisions about prostate biopsies

Yesterday morning, a newly published paper was brought to my attention. It reports that use of the Prostate Health Index or phi test in a partially prospective study can and did change urologists’ opinions about whether selected patients really do or don’t need to have a prostate  biopsy. … READ MORE …

Risk, genomic risk, and prognosis of risk for prostate cancer metastasis and death

A recently published study in European Urology has again (partially) validated the utility of a specific type of genomic testing as a way to project risk for progressive disease in men initially diagnosed with localized prostate cancer. … READ MORE …

MRI data and genomic data are telling us different things about prostate cancer risk

A new paper just published on line in the journal PLoS One is entitled, “Association between a 17-gene genomic prostate score and a multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa)”. … READ MORE …

Genomic testing for localized prostate cancer: an update

A relatively brief, current, full-text review article by Loeb and Ross is available on the Medscape web site and discusses the three currently available tests for assessment of genomic risk for men with localized forms of prostate cancer. … READ MORE …